Drugs / AP402
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06669975 | Apr 2025 → Dec 2026 expected | neoplasm | AP Biosciences Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06669975 ↗ |
| Route | Intravenous | “where an IV infusion of AP402 will be administered once every 2 weeks” NCT06669975 ↗ |